Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PRTX007 + Pembrolizumab in Stage III Melanoma
NCT07565285Phase 2Recruiting
- Sponsor
- Primmune Therapeutics
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of prtx007 in melanoma, sponsored by Primmune Therapeutics. Started Jul 2026; status: recruiting.
02
Drugs
prtx007
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07565285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565285.